Kinase News and Research

RSS

NCI explores how erectile dysfunction drugs work to prevent colon cancer

Erectile dysfunction drugs may be able to help prevent or even treat colon cancer, researchers say.

3 Oct 2013

Discovery paves way for new therapeutic strategies to protect heart health of diabetes patients

UC Davis Health System researchers have identified for the first time a biological pathway that is activated when blood sugar levels are abnormally high and causes irregular heartbeats, a condition known as cardiac arrhythmia that is linked with heart failure and sudden cardiac death.

1 Oct 2013

Intercalated erlotinib/chemotherapy shows mixed results in NSCLC

A study comparing erlotinib alone with erlotinib intercalated with chemotherapy has failed to demonstrate a clear advantage of the combination strategy when used to treat relapsed patients with non-small-cell lung cancer, Dutch researchers report.

30 Sep 2013

Women with recurrent ovarian cancer survive longer after treatment with cediranib

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress.

30 Sep 2013

Discoveries pave way for use of new therapies for advanced thyroid cancer

For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options. But now, building on recent discoveries about the genetics and cell signaling pathways of thyroid tumors, researchers are developing exciting new weapons against the disease, using kinase inhibitors that target tumor cell division and blood vessels.

30 Sep 2013

Icotinib matches gefitinib in NSCLC second or third line

Icotinib has been found to be noninferior to gefitinib in patients with non-small-cell lung cancer, according to reports from the phase III Chinese double-blind ICOGEN study.

26 Sep 2013

Targeting cell-division cycle may lead to improved outcomes for patients with medulloblastoma

A new experimental approach to treating a type of brain cancer called medulloblastoma has been developed by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham).

26 Sep 2013

Researchers lead two major trials to test potential treatments for asbestos-related cancer

University of Leicester researchers are leading two major trials into treatments for a type of cancer which affects those exposed to asbestos.

23 Sep 2013

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis.

18 Sep 2013

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.

17 Sep 2013

Research finding offers new approach to treating melanoma

Scientists at Sanford-Burnham Medical Research Institute today announced the discovery that a gene encoding an enzyme, phosphoinositide-dependent kinase-1, plays an essential role in the development and progression of melanoma. The finding offers a new approach to treating this life-threatening disease.

17 Sep 2013

Current criteria for ALK positive lung cancer needs to be redefined

A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. The findings suggest that doctors should look closer at borderline or atypical ALK-negative cases, and could widen the population of lung cancer patients offered treatment with crizotinib or other ALK-inhibitor drugs.

12 Sep 2013

Ventana gets CFDA approval for VENTANA ALK immunohistochemistry assay

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the approval of the VENTANA ALK immunohistochemistry assay by the Chinese Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's CFDA-approved oncology product XALKORI (crizotinib).

12 Sep 2013

Astrazeneca Licenses Merck's Cancer Candidate MK-1775

...

11 Sep 2013

Chemists Find New Way To Put The Brakes On Cancer

...

10 Sep 2013

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found.

9 Sep 2013

Researchers investigate importance of STAT1 phosphorylation in NK cells

Since its discovery in the early 1990s, the protein STAT1 (Signal Transducer and Activator of Transcription 1) has been found to be central in passing signals across immune cells, ensuring that our bodies react quickly and appropriately to threats from viruses or other pathogens.

7 Sep 2013

Assay aids ALK fusion detection in lung adenonocarcinoma

A fully automated immunochemistry assay is highly sensitive and specific for detecting anaplastic lymphoma kinase fusion in primary lung adenocarcinomas, Chinese researchers report.

6 Sep 2013

Inner-ear dysfunction can increase hyperactivity, say researchers

Behavioral abnormalities are traditionally thought to originate in the brain. But a new study by researchers at Albert Einstein College of Medicine of Yeshiva University has found that inner-ear dysfunction can directly cause neurological changes that increase hyperactivity.

6 Sep 2013

Chemotherapy best second-line option for EGFR wild-type NSCLC

Chemotherapy is more effective than erlotinib as second-line therapy in people with advanced non-small-cell lung cancer and wild-type epidermal growth factor receptor genotype, a randomized controlled trial has found.

5 Sep 2013